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DOI 10.1016/j.stem.2010.06.003The direct reprogramming of somatic
cells to produce induced pluripotent
stem cells (iPSCs) is a prominent recent
advance in stem cell biology (Takahashi
and Yamanaka, 2006). Generation of
iPSCs without genomic integration of
extrinsic genes is highly desirable.
Initially, human dermal fibroblasts were
used to derive human iPSCs (hiPSCs)
(Takahashi et al., 2007; Yu et al., 2007).
However, recent studies have shown
that other human somatic stem cells can
be used (Aasen et al., 2008; Eminli et al.,
2009; Kim et al., 2009; Ye et al., 2009). It
is difficult to obtain human somatic stem
cells, but human terminally differentiated
circulating T cells (hTDCTCs) are readily
available from peripheral blood. Here,
we show that a combination of activated
T cell cultivation and a temperature-sensi-
tive mutated Sendai virus (SeV) that
encodes human OCT3/4, SOX2, KLF4,
and c-MYC allows the generation of
hiPSCs easily, efficiently, and safely
within a 1 month time frame.
Sampling of peripheral blood is one of
the least invasive procedures performed
routinely in clinics, and surplus peripheral
blood samples are often left unused after
clinical examinations. Among peripheral
blood mononuclear cells (PBMCs),
T cells can be readily cultured in vitro by
means of a plate-bound anti-CD3 mono-
clonal antibody and recombinant (r)IL-2
(Desai-Mehta et al., 1996), and we used
such an approach to expand hTDCTCs
from peripheral blood samples. From
1 ml of whole blood, PBMCs were sepa-
rated on a Ficoll gradient and thencultured with plate-bound anti-CD3
monoclonal antibody and rIL-2 (Fig-
ure 1A). Although PBMC fractions contain
lymphocytes and monocytes, T cells are
selectively cultured under these condi-
tions. In culture, the number of activated
T cells increased gradually but consis-
tently. Five days after blood sampling,
the cultured cells were morphologically
identical to pure CD3-positive T cells
collected by fluorescence-activated cell
sorting (FACS) (Figure 1B). We used
a whole-PBMC culture method because
it is technically simpler than FACS, in
which the sorted cells are frequently
damaged by laser emission and the
process of single-cell sorting.
To avoid transgene integration during
iPSC generation, we used an SeV vector,
which is a minus-strand RNA virus that is
not integrated into the host genome and
is not pathogenic for humans (Li et al.,
2000). We used a temperature-sensitive
mutated SeV vector in these experiments
to reduce transgene expression and SeV
residue in generated lines. This form of
SeV vector generates weaker transgene
expression and cannot proliferate at stan-
dard culture temperatures (data not
shown). SeV can be efficiently transduced
into human T cells and can express exog-
enous genes (Okano et al., 2003). We first
introduced green fluorescent protein
(GFP) into human T cells by SeV in
a dose-dependent manner; toxicity for
the infected cells was minimal at the virus
dosages used (Figure 1C). To generate
iPSCs from hTDCTCs, we used SeV to
deliver multiple transgenes that encodedCell Stemstem cell-specific transcription factors,
such as OCT3/4, SOX2, KLF4, and
c-MYC, into cells on day 6 of culture.
Two days after gene introduction, the
cells were replated onto feeder layers of
SNL cells. On day 9, the cells were trans-
ferred to human ES cell (ESC) medium
that contained 4 ng/ml bFGF. Within 3
weeks of infection, we identified a colony
that resembled human ESCs (hESCs)
among the T cell derivatives. On day 25,
colonies that were larger and morpholog-
ically similar to hESC-like colonies were
picked (Figure 1D). Of these initial colo-
nies, which were identified by crystal
violet staining, most were positive for
alkaline phosphatase (ALP), which is
a characteristic marker of stem cells (Fig-
ure 1E). T cells that had been transfected
with SeV vectors carrying OCT3/4, SOX2,
KLF4, and c-MYC were plated onto mito-
mycin C-treated SNL feeder cells at 5 3
104 cells per 10 cm dish. Around day 25
after blood sampling, the number of
ALP-positive hESC-like colonies was
counted and approximately 50 colonies
were observed at MOI 20 (Figure 1E) (an
efficiency of 0.1%). Moreover, the effi-
ciency of iPSC colony generation was
dependent upon the dosage of virus
used for gene introduction (Figure 1F).
We named these established T cell-
derived iPSCs as ‘‘TiPS cells (TiPSCs).’’
After expansion, the cloned TiPSCs dis-
played typical hESC/iPSC morphology
and had a normal karyotype (Figures
S1A and S1B available online).
To confirm that the TiPSCs had the
characteristics of typical ESC/iPSCs, weCell 7, July 2, 2010 ª2010 Elsevier Inc. 11
Figure 1. hTDCTCs-Derived iPSC Colonies
(A) Strategy used in the present study for reprogramming T cells.
(B) Morphologies of T cells derived from whole PBMCs or FACS-sorted T cells grown in the presence of
CD3 antibody and rIL2.
(C) Efficient GFP introduction by SeV in T cells transfected at an MOI of 3 or MOI of 20.
(D) Typical ESC-like iPSC colonies on day 25 after blood sampling.
(E) Examples of 10 cm dishes stained for ALP on day 25, showing numerous ALP-positive colonies of
T cells that were transfected at an MOI of 5 or MOI of 20.
(F) Numbers of ALP-positive colonies in relation to multiplicity of infection.
(G) RT-PCR analyses for the hESC marker genes NANOG, OCT3/4, SOX2, KLF4, c-MYC, GDF3, REX1,
DPPA2, and DPPA4 and the transgenes OCT3/4, SOX2, KLF4, and c-MYC.
(H) Immunofluorescence staining for pluripotency and surfacemarkers (NANOG, OCT3/4, SSEA3, SSEA4,
TRA-1-60, and TRA-1-81) in TiPS 05, 07, and 18. Scale bars represent 500 mm.
(I) Bisulfite sequencing analysis of the NANOG andOCT3/4 promoter regions in peripheral T cells, hESCs,
and hTiPSCs 05, 07, and 18. Each row of circles for a given amplicon represents the methylation status of
the CpG dinucleotides in one bacterial clone for that region. Open circles represent unmethylated CpGs;
closed circles represent methylated CpGs.
See also Figure S1 and Table S1.
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Reverse-transcription PCR (RT-PCR)
analyses revealed that the TiPS 05, 07,
and 18 clones expressed ESC marker
transcripts for NANOG, OCT3/4, SOX2,
KLF4, c-MYC, GDF3, REX1, DPPA2, and
DPPA4. The original T cells also ex-
pressed c-MYC at a basal level, as previ-
ously reported (Douglas et al., 2001). In12 Cell Stem Cell 7, July 2, 2010 ª2010 Elsevthe TiPSCs, the OCT3/4, SOX2, KLF4,
and c-MYC transgenes were lost after
several passages (Figure 1G; Fig-
ure S1C). Immunostaining revealed that
the TiPSCs expressed the Nanog, Oct3/4,
SSEA3, SSEA4, Tra-1-60, and Tra-1-81
proteins (Figure 1H). High telomerase
activity is also an important characteristic
of iPSCs, and, appropriately, TiPSCsier Inc.showed high levels of telomerase activity
(Figure S1D). Another signature of iPSCs
is epigenetic remodeling. We used bisul-
fite sequencing to examine the methyla-
tion status of the NANOG and OCT3/4
promoters. T cells, which do not express
NANOG orOCT3/4, showedmostlymeth-
ylated CpGs in those promoters. hESCs,
which do express NANOG and OCT3/4,
showed unmethylated CpGs in those pro-
moters. As in hESCs, the CpGs in these
promoter regions were predominantly
unmethylated in the TiPSCs (Figure 1I).
These results suggest that SeV-mediated
gene transfer successfully reprograms
hTDCTCs.
Somatic recombination of T cell
receptor (TCR) genes generates a diverse
T cell repertoire that allows adaptation for
antigen responses (Krangel, 2009). To
confirm that the TiPSCs were derived
from hTDCTCs, we analyzed TCR rear-
rangements. A hallmark of the TCR-
b locus is developmentally ordered
recombination, with Db-to-Jb recombina-
tion preceding Vb-to-DbJb recombina-
tion. We performed capillary electropho-
resis of the PCR products for the
genomic DNA of the TCR-b regions. As
a positive control, we used monoclonal
T cells, which are derived from patients
with lymphocyte malignancies and show
a specific peak, because these T cells
have only a single genetic variation in their
TCR regions (Figure S2A). Peripheral
T cells from people without lymphocytic
diseases are polyclonal, with diverse
genetic variations in their TCR rearrange-
ments, and show a broad and low band
without a specific peak. ESCs do not have
TCR rearrangements and do not show a
specific positive peak. The TiPS 05, 07,
and 18 cell lines showed specific peaks
for Db/Jb recombination. TiPS 05 showed
Vb/Jb2 recombination. TiPS 07 and TiPS
18 showedVb/Jb1,2 recombination, albeit
with different bands (Figure 2A). TCR re-
arrangement is specific for T cell deve-
lopment, so these results confirm that
TiPSCs are derived from T cells. They
also indicate that the TiPS 05, 07, and
18 lines originated from different T cells.
We analyzed the rearrangement pattern
of 10 independent TiPSCs and confirmed
that every TiPSCs showed different rear-
rangement pattern (Figure S2A).
We also performed global gene expres-
sion analyses with DNA chips. Scatter
plot analyses revealed global gene
Figure 2. Detail Characterizations of TiPSCs
(A) Characterization of the TCR-b rearrangement by capillary electrophoresis. The green line is derived
from the band for the Jb1 gene, and blue line is derived from the band for the Jb2 gene. TiPS 05 shows
rearrangements of Vb/Jb2 and Db/Jb. TiPS 07 shows rearrangements of Vb/Jb1,2 and Db/Jb. TiPS 18
shows rearrangements of Vb/Jb1,2 and Db/Jb.
(B) Scatter plots comparing the global gene expression profiles of T cells and TiPS cells, dermal fibroblast-
derived iPSCs (G4) and ESCs, ESCs and TiPSCs, and dermal fibroblast-derived iPSCs (G4) and TiPSCs.
The black lines indicate 2-fold differences in gene expression levels between the paired cell populations.
The transcript expression levels are shown on a log2 scale. The expression levels of NANOG, OCT3/4,
SOX2, and c-MYC are shown.
(C) Heat map analyses of hESCs, dermal fibroblast-derived iPSCs, TiPSCs, and the parental human
T cells.
(D) Gross morphology, hematoxylin and eosin-stained representative teratomas derived from TiPS 05.
Cell Stem
Cell Stem Cell
Brief Reportexpression differences between periph-
eral T cells and TiPSCs. Comparison of
hESCs and human dermal fibroblast-
derived iPSCs, hESCs, and human
TiPSCs (hTiPSCs), and dermal fibro-
blast-derived iPSCs and TiPSCs showed
high levels of similarity (Figure 2B). Heat
map analysis showed that the global
gene expression profiles were overall
similar in ESCs, dermal fibroblast-derived
iPSCs, and TiPSCs, and different from
T cells (Figure 2C). To further demonstrate
the pluripotency of hTiPSCs, they were
transplanted into the subcutaneous tissue
of severe combined immunodeficient
(SCID) mice. Six to eight weeks after
injection, each TiPSC line tested gave
rise to teratomas that contained deriva-
tives of all three germ layers (Figure 2D;
Figure S2B). We also examined the
in vitro differentiation potential of TiPSCs.
Each TiPSC line tested generated
embryoid bodies that contained deriva-
tives of all three germ layers (Figure 2E).
These results indicate that hTiPSCs are
pluripotent stem cells. Although it was re-
ported that Trp53 null murine T cells could
be reprogrammed into iPSCs (Hong et al.,
2009),wehavesuccessfully reprogrammed
wild-type human T cells. In our hands, the
efficiency of conventional retrovirus-medi-
ated gene transfer into wild-type human
T cells was very low compared to SeV
(data not shown). In our view, the efficiency
of gene transfer is a major determining
factor in successful iPSC generation.
With current technology, if iPSC-
derived mature cells are transplanted
into diseased patients, there is no good
procedure for following their progeny,
which could eventually form malignant or
benign tumors. In animal models, several
marker genes can be used to chart the
progression and consequences of iPSC-
derived mature cell transplantation, such
as GFP and luciferase. However, it is not
desirable to insert exogenous marker
genes into the genomes of hiPSCs for clin-
ical use. TiPSCs, however, already have a
traceable genetic signature through TCR
locus rearrangement. Consistent with this
idea, teratomas derived from TiPSCs had(E) Immunofluorescence staining for Sox17 (endo-
dermal marker), aSMA (mesodermal marker), and
Nestin (ectodermal marker) in each TiPSC-derived
differentiated cell.
(F) Characterization of the TCR-b rearrangement
for teratoma from TiPS 18.
See also Figure S2 and Table S2.
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(Figure 2F; Figure S2C). Therefore, the
descendents of TiPSCs can be identified
by analyzing their TCR rearrangement
patterns.
In conclusion, we have developed
a minimally invasive method for hiPSC
generation without genomic integration
that uses low numbers of hTDCTCs from
peripheral blood. This method has advan-
tages for research into stem cell reprog-
ramming, TCR rearrangement, immuno-
logic disorders, and the development of
genetic markers for future applications of
regenerative medicine. TiPSCs may well
be relatively easy touse inaclinical setting.
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